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Monoclonal antibodies (mAbs) have become vitally important to modern medicine and are
currently one of the major biopharmaceutical products in development. However, the high
clinical dose requirements of mAbs demand a greater biomanufacturing capacity, leading to
the development of new technologies for their large-scale production, with mammalian cell
culture dominating the scenario. Although some companies have tried to meet these demands
by creating bioreactors of increased capacity, the optimization of cell culture productivity in
normal bioreactors appears as a better strategy. This review describes the main technologi-
cal progresses made with this intent, presenting the advantages and limitations of each pro-
duction system, as well as suggestions for improvements. New and upgraded bioreactors
have emerged both for adherent and suspension cell culture, with disposable reactors
attracting increased interest in the last years. Furthermore, the strategies and technologies
used to control culture parameters are in constant evolution, aiming at the on-line multi-
parameter monitoring and considering now parameters not seen as relevant for process opti-
mization in the past. All progresses being made have as primary goal the development of
highly productive and economic mAb manufacturing processes that will allow the rapid
introduction of the product in the biopharmaceutical market at more accessible prices.
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Introduction
In the last decades, monoclonal antibodies (mAbs) have
become increasingly important in terms of medical research,
diagnosis, and therapy. They constitute more than 30% of
total biopharmaceutical production1,2 and are the largest class
of proteins currently under clinical trials.3 Several mAbs have
been approved for use in therapeutic applications, as summar-
ized in Table 1 (for a more extensive and detailed list that
includes mAbs approved for diagnostic purposes as well as
mAbs under development, consult the Immunogenetics
(IMGT) webpage http://imgt.cines.fr/textes/IMGTrepertoire/
GenesClinical/monoclonalantibodies/#Approval_antibodies).
The major percentage of the mAbs approved and under
trials is produced by mammalian cells4 because of their abil-
ity to perform human-like post-translational modiﬁcations
that result in full-active product.5
Generally, therapies with mAbs require the use of high
doses over prolonged periods of time.6 Therefore, the pro-
duction of these products needs to be done at large scale to
meet the market demands.6 Moreover, it is desirable to have
economic, highly productive, and consistent manufacturing
processes, able to deliver health beneﬁts to patients in a
quick way.6 The achievement of an economic highly produc-
tive process currently constitutes a major biotechnological
challenge.7 With this aim, several production systems have
been developed, with frequent updates and improvements,
resulting in a wide range of available technologies for large-
scale mAb production. In this article, it is intended to give a
critical review of these systems, pointing their strengths,
recent advances, as well as major limitations that still need
to be surpassed.
Production Systems
In the laboratory, conventional low-density cell culture
methods are used for production of mAbs at low concentra-
tions (1–100 lg/mL).3 This small-scale cell culture provides
sufﬁcient amounts for research and diagnostic purposes.
However, the market needs for therapeutic products require
large-scale manufacturing capacity,3 with demands on mAbs
of 100–1,000 kg/year, which can only be achieved in large
bioreactors and by efﬁcient processes that produce several
kg/day.8,9
Systems for small-scale production
Small-scale culture systems usually have a simple design
and a low level of instrumentation and control.10 In these
systems, cells are usually grown adherently, because this is
the normal/physiological mode of growth of mammalian
cells, and the process of adaptation to suspension can be
time-consuming. Nevertheless, because adherent culture has
the major drawback of limited surface area for growth,11
some small-scale systems for suspension culture have also
been developed.
Correspondence concerning this article should be addressed to M.
Henriques at mcrh@deb.umiho.pt.
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Adherent Culture. For adherent culture, the typical sys-
tems used in laboratory scale are T-ﬂasks, petri dishes, and
multiwell plates. These systems are maintained in a humidi-
ﬁed carbon dioxide (CO2) incubator to provide a controlled
environment for cell growth.
In anchorage-dependent cultures, the cell concentration
possible to achieve is directly proportional to the surface
area available for growth.10 Therefore, the scale increase for
these cultures involves the ampliﬁcation of the growth sur-
face. One way to provide larger surface areas is to use multi-
layered stacked plate systems, such as Cell Factory
(NalgeNunc) and CellCube (Costar) (Figures 1a,b).12–14 In
these systems, because of the increased surface-to-volume
ratio, high cell concentrations can be achieved, which in the
case of CellCube is added by the continuous medium
circulation that supplies oxygen and nutrients to the cells.14
However, heterogeneity of ﬂuid ﬂow has been observed in
this system, resulting in nonuniform cell growth patterns and
shear stress.14 Furthermore, both Cell Factory and CellCube
operation are usually tedious, time-consuming, and with
inefﬁcient utilization of space.13
Another system commonly used to increase surface area,
and therefore obtain higher cell and product concentrations,
is roller bottles (Figure 1c).15,16 In this technology, cells are
seeded into the roller bottles that are ﬁlled to 10–30% of
their capacity with medium and slowly rotated, allowing
cells to adhere and assuring their regular wetting.4 Apart
from the increased surface area for growth and low shear
rates,17,18 roller bottles have other advantages, such as very
high oxygen transfer rates (supplied by the ample bottle
‘‘headspace’’4) and the ease of scale-up that is simply done
by increasing the number of units handled in parallel.4,19
However, the handling of a large number of roller bottles
simultaneously can be tedious,13 labor-intensive,20 prone to
contamination, and difﬁcult to control product quality.20 This
has led to the development of automated systems to handle
roller bottle cultures (e.g., the RollerCell system marketed
by Cellon, SA21).22
Furthermore, roller bottles only operate as batch or fed-
batch systems, which prevents them from achieving cell
densities and antibody secretion rates as high as the ones
attained in continuous perfusion systems.4,19,23 A possible
way to overcome this limitation is to use roller bottles oper-
ating on apparatuses that provide a continuous supply of
nutrients and oxygen to the cells.19,23 This can be done by
using a pump that delivers the culture medium from a fresh
medium reservoir into the growth chamber of the bottle (spi-
roll bottle19) or by using a medium recirculation loop
(CPRB—continuous perfusion roller bottle23) (Figures 1d,e).
Higher cell densities can then be achieved in these models,
as well as maintenance of cultures over longer periods of
time, resulting in increased volumetric productivities.
All the systems mentioned, although achieving higher cell
concentrations and productivities than the traditional labora-
tory methods of culture (T-ﬂask, petri dishes, and multiwell
plates), are not commonly used for large-scale industrial pro-
duction. This is due to their limitations in terms of high costs
(labor, equipment, and consumables), considerable risk of
contamination, and poor control of culture parameters.10
Suspension Culture. When compared with adherent cul-
ture, in suspension systems cell concentration is independent
of the surface area available, which allows increased cell
densities and consequently higher product concentrations.
The systems used for adherent culture (i.e., T-ﬂasks, petri
Table 1. Monoclonal Antibodies Approved for Clinical Application Until 2009
Product Company Clinical Indication Approval
ORTHOCLONE Ortho Biotech Acute kidney transplant rejection 1986
OKT3
VR
Heart transplant rejection, liver transplantation 1993
REOPRO
VR
Centocor/Eli Lilly Percutaneous transluminal coronary angioplasty 1994
PANOREX
VR
Centocor/GlaxoSmithKline Colon cancers 1995
ZENAPAX
VR
F. Hoffmann-La Roche Acute kidney transplant rejection 1997
MABTHERA
VR
/RITUXAN
VR
Biogen IDEC/Genzyme/F.
Hoffmann-La Roche
Follicular CD20 positive non-Hodgkin’s
B-cell lymphoma (NHL),
non-Hodgkin’s B-cell lymphoma (NHL)
1997
Rheumatoid arthritis (RA) 2006
SIMULECT
VR
Novartis Renal transplant rejection 1998
SYNAGIS
VR
Abbott/MedImmune Respiratory Syncytial virus disease 1998
HERCEPTIN
VR
F. Hoffmann-La Roche/Genentech Metastatic breast cancers overexpressing ERBB2 1998
REMICADE
VR
Centocor Crohn’s disease 1998
Ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis
1999
Rheumatoid arthritis (RA) 2001
MYLOTARG
VR
Wyeth Acute myeloid leukemia 2000
CAMPATH
VR
/MABCAMPATH
VR
Berlex/Genzyme/Millennium B cell chronic lymphocytic leukemia 2001
HUMIRA
VR
/TRUDEXA
VR
Abbott Psoriatic and rheumatoid arthritis 2002
ZEVALIN
VR
Biogen IDEC/Schering AG Non-Hodgkin’s B-cell lymphoma 2002
RAPTIVA
VR
Genentech/Merck Serono
International/Xoma
Psoriasis 2003
XOLAIR
VR
Genentech/Novartis/Tanox Allergic asthma, severe persistent asthma 2003
BEXXAR
VR
GlaxoSmithKline/Corixa Follicular CD20 positive non-Hodgkin’s
B-cell lymphoma (NHL)
2003
AVASTIN
VR
Genentech Metastatic colorectal cancers, metastatic
non-small-cell lung cancers
2004
ERBITUX
VR
Merck & Co/ImClone Metastatic colorectal cancers 2004
TYSABRI
VR
Biogen IDEC/Elan Multiple sclerosis 2004
THERACIM
VR
YM BioSciences Glioma cancers 2004
VECTIBIXTM Amgen Colorectal cancers 2006
LUCENTIS
VR
Genentech/Novartis Neovascular age-related macular degeneration 2006
SOLIRISTM Alexion Paroxysmal nocturnal hemoglobinuria (PNH) 2007
CIMZIA
VR
Celltech, UCB Crohn’s disease 2008
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dishes, and microtiter plates) can also be used for suspension
cell propagation.10 Particularly, shaken microtiter plates are
highly used for purposes of screening and optimization in
cell culture,24 although the problem of evaporation limits its
use for extended cultures.4
For the same purpose of screening, in media development
trials, centrifuge tubes with ventilated caps can also be used
for culturing cells in suspension.10,25
However, despite the fact that adherent systems can be
used for suspended cultures, more adequate methods are
available (Figure 2). These include shake ﬂasks,26,27 roller
bottles,19 and spinner ﬂasks,10 that have been used for culti-
vation of many different suspension cell lines for a variety
of applications within preclinical research, process develop-
ment, and for expansion of inoculum in production.4,10
The advantages of these suspension-speciﬁc systems com-
paring to the stationary methods include the non-cell-adher-
ent materials used in their construction, as well as a proper
design that are ideal for maintaining a suspension culture
without problems of cell deposition or adherence. Although
oxygen transfer is improved because of the larger gas/liquid
surface and agitation, oxygen limitations are still a major
drawback that does not allow high cell densities to be
achieved.4,10,28 Attempts to minimize this problem include
sparging with Oxygen (O2)/air, the superspinner
29 (Figure
2c) that uses microporous membranes through which an air/
CO2 mixture is pumped, and the CELLine 1000 device,
30
(Figure 2d) which has separate growth and medium cham-
bers that allow more frequent and easier medium changes,
with direct oxygenation and easy product isolation.
This system improves oxygen transfer rates, supporting
high cell density (107–108 cells/mL) and generating a high
mAb concentration (0.7–2.5 mg/mL) within a period of 2
months, but is still limited to a 1–2 L volume of culture per
batch.30
The limitations of oxygen transfer and poor control of the
culture parameters inherent to the aforementioned devices
only allow for small- or medium-scale production. To
achieve large-scale production, other systems had to be
developed.
Figure 1. Systems for adherent culture in small scale.
(a) Cell Factory (www.ﬁsher.co.uk), (b) Cell Cube (http://catalog2.corning.com), (c) Roller Bottle (www.sigmaaldrich.com), (d) Spi-roll Bottle,19
and (e) CPRB.23
Figure 2. Systems for suspension culture in small scale.
(a) Shake ﬂasks (www.sigmaaldrich.com), (b) Spinner
ﬂasks (www.sigmaaldrich.com), (c) Superspinner (www.
pharmaceuticalonline.com), and (d) CeLLine 1000 (www.
sartorius-stedim.com).
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Systems for large-scale production
The high demands for mAbs gave rise to the development
of different bioreactors and culture systems for large-scale
production in mammalian cell culture. These systems are
constantly evolving to overcome some key barriers of large-
scale processing, such as oxygen supply limitations, waste
product accumulation, the need for more sophisticated pro-
cess control, shear sensitivity of animal cells, and the chal-
lenges of growing adherent cell lines at large scale.31
Although some of these limitations have been surpassed,
new ones have arisen. These include the maximization of the
productivity while maintaining product quality, removal of
all animal-derived components from cell culture medium,
minimization of contamination during large-scale production,
and control of CO2 removal.
9
For large-scale production, suspension cell-culture proc-
esses are usually the system of choice. Nevertheless, adher-
ent culture systems are also being developed, because they
can be indispensable to certain applications.
Suspension Culture. Suspension cell systems are the
usual choice for large-scale production because of the well-
understood principles of scale-up, the ease of process con-
trol,9 and the higher surface-to-volume ratio when compared
with the adherent cell systems,10 which result in more efﬁ-
cient processes.
For culturing cells in suspension, agitation and aeration
are critical and can cause shear damage to the cells. These
negative effects can be minimized by using shear-protecting
agents, such as Pluronic F68 (proposed mechanism of action
reviewed by Gigout et al.32) or by appropriate reactor design
and control.9 It should be taken into account that although
many cell types can be adapted to suspension, this is still
limiting the choice of cell line and is time-consuming,
increasing the timeline for process development.
The most commonly used suspension culture systems for
production of mAb are the stainless steel stirred tank,33 the
airlift,34 and disposable28 bioreactors. Some speciﬁc advan-
tages and limitations of these reactors, as well as recent
developments, will be addressed later.
Stainless steel stirred tank bioreactor. The traditional
and most widely used bioreactor type for mAb production is
the stainless steel stirred tank bioreactor (STR) (Figure
3).9,10,35 This is mainly due to the broad knowledge and ex-
perience acquired from microbial fermentation.10 This
results in better characterized and familiar scale-up princi-
ples and mechanical designs for sterilization and cleaning,
when compared with other bioreactor types.10 This know-
how also facilitates the regulation/approval of the process of
production, because the regulatory agencies are experienced
with products obtained from STR in different modes of
operation.10
Other advantages of STR include the high mass/gas-trans-
fer coefﬁcient values,35 the high ﬂexibility35 in terms of ap-
plicable working volumes (up to 15,000 L37), and the
suitability for different cell types, operation modes, and
products, which results in reduction of costs.10
Furthermore, good culture conditions such as temperature
control, culture pH, dissolved oxygen (DO) level, low agita-
tion rate, and aeration with mixed gas and well-controlled
conditions are supported and fulﬁlled by this bioreactor.35
This accurate control of culture conditions allows robust
mAb production in STR with most commercially available
cell lines. However, the productivities obtained could be
further improved if the factors causing stress to the cells
could be suppressed, such as shear and bubble damage
caused by mechanical agitation and gas sparging.38 Conse-
quently, it is one of the main aims in reactor design, with
advances being made on the impeller design, to minimize
shear damage to cells and consequently improve cell density
and mAb production.39
Air-lift reactors. In addition to STRs, airlift reactors
(Figure 4) are also widely used for suspension animal cell
culture.41,42 They can be considered as a type of bubble
column, due to mixing being provided by the introduction of
gas bubbles at the base of a tall column.43 This results in
gentler mixing action and suitability for shear-sensitive cells
than STR.43 Nevertheless, gas sparging is still a concern in
terms of cell damage and death, and therefore it is an impor-
tant factor to regard in reactor design and scale-up.38
Other advantages of air-lift bioreactors over STR are the
easiest scale-up and the more reliable sterile operation (con-
sequence of the absence of moving parts and mechanical
seals).38,44 Nevertheless, the air-lift reactor is not as widely
used as STR because of less know-how, but also to the lim-
ited ﬂexibility in terms of working volume (only up to 2,000
L44,45) and limited suitability for microcarrier culture,10
which has been considered impractical.46,47
Disposable bioreactors. Although stainless steel bioreac-
tors are still the major choice for large-scale production,6 in
recent years advances have been observed in disposable sys-
tems for cell cultivation that have risen the interest in their
use at production scale.48
Disposable bioreactors can be very advantageous for the
manufacturing process in the areas of cleaning, sterilization,
set-up, and turn-around time between runs.6,48,49 Further-
more, they eliminate the chance of cross-contamination
between process runs,49 reduce the expensive capital
Figure 3. Simpliﬁed diagram of a stainless steel stirred tank
bioreactor.
(A) Impeller drive, (B) marine impeller, (C) cell suspension,
(D) water jacket, (E) pH probe, (F) DO probe, (G) removable
headplate, (H) condenser, (I) gas ﬁlter, and (J) headspace.36
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investment associated with stainless steel bioreactors,6 and
result in substantial cost savings in initial investment, labor,
equipment, facility design, and validation.49 Indeed, valida-
tion is less complex because of the elimination of the sterili-
zation and cleaning procedures, as well as the use of fewer
reusable components that result in fewer items to be
tracked.49
However, these bioreactors are still limited by their culture
volume and, therefore, are mostly used for smaller scale cul-
tivations, for seed culture expansion and for inoculation of
the large conventional bioreactors.49,50 Nevertheless, bioreac-
tors up to 2,000 L are currently available, such as the
HyClone
VR
, Millipore
VR
(CellReadyTM), or Xcellerex
VR
(XDRTM) single-use bioreactors, that combine the well-
known STR design with the advantages of disposability.
Among the disposable reactors available, the wave bio-
reactor (Figure 5) is particularly relevant,28,51 with strong
demand for applications of plant,52 insect,28,53 and different
mammalian cells.28,54–56 This bioreactor system, ﬁrst
described by Singh,28 consists of a disposable, ﬂexible, ster-
ile plastic bag (CellBagTM) that sits on a rocking thermo-
platform.28,53,57 The cellbags are ﬁlled with cell suspension
up to half their capacity (from 2 L, for small-scale culture,
up to 1,000 L, for large-scale culture) and inﬂated with
air.28,53,57 The rocking motion of the cellbag induces undula-
tion to ensure good nutrient distribution, off-bottom suspen-
sion, and a greater and constantly renewed surface that
increases oxygen transfer without shear damage.28,53,57
Oxygen supply is given by headspace aeration,48,53 and the
headspace can be ﬁlled or continuously gassed with the
desired gas mixture.28 The system can operate in CO2 incu-
bators or stand-alone in combination with a heater and a
CO2 control unit.
10,28
The wave bioreactor can be valuable for cell/gene therapy
applications (primary cell cultivation, rapid expression/
screening of hundreds of genes),28 rapid material supply dur-
ing early stage clinical studies,49 process development and
clinical manufacturing.57 It operates in different culture
modes, including perfusion, which can be performed using
different cell-retention mechanisms for the high-efﬁcient pro-
duction of mAbs.58
The combined advantages of a fully closed, disposable
system with process monitoring capabilities (pH and DO)
make the wave bioreactor highly attractive over traditional
systems for animal cell culture, such as shake ﬂasks and
STR,57 although with limitations in culture volume.
Adherent Culture. Although large-scale production of
mAbs by mammalian cells is usually done in suspension cul-
ture, continuous efforts are being made to develop high-den-
sity adherent cell culture systems. This is a consequence of
the adherent growth being the natural state for mammalian
cells,4 with problems related to suspension culture, such as
sensitivity to hydrodynamic shear forces59,60 and time-con-
suming processes of adaptation,61,62 not being an issue in the
adherent cultures.
However, attachment-dependent cell culture has, as men-
tioned earlier, the major limitation of low surface-to-volume
ratio that results in low cell densities. Therefore, to scale-up
these cultures with higher cell densities, it is important to
maximize the surface-to-volume ratio.9,11 On account of that,
many immobilization systems/bioreactors have been devel-
oped, where cells are usually immobilized on/inside particles
that are suspended in culture medium.63 The most well-
known system for culture of adherent cells is microcarrier
culture,64,65 which can be performed in different bioreactors,
with STR being the most common.66 Other immobilization
systems include small beads of different materials67 (aga-
rose,68 gelatin and alginate67,69), gel particles (collagen70),
membranes,71–73 and ﬁbers.74–77
All these systems are ideal for perfusion culture,11 which
increases cell concentration in the reactor (107–108 cells/mL)
and extends the productive lifetime of cells,60,74 resulting in
increased levels of mAb productivity when compared with
suspension culture.60,74 Furthermore, immobilized cell
Figure 5. Schematic diagram of the disposable wave
bioreactor.28
Figure 4. Simpliﬁed diagram of an airlift bioreactor.40
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reactors have other advantages such as simplifying down-
stream processing because of cell retention,78 which provides
cell-free products,60,74 creating a favorable microenviron-
ment for cell growth and mAb production.60,78 However,
these bioreactors still have limitations that result in a prob-
lematic long-term use and scale-up. For example, in bioreac-
tors that use beads, destruction of the beads can occur with
cell leaking and washout, resulting in declined mAb produc-
tion over time.77 In membrane and ﬁber bioreactors, cell
degeneration and accumulation of nonviable cells over long-
term operation occurs, with biomass build-up, resulting in
poor mass transfer.79
The particular advantages and limitations of each of the
main immobilization systems used are reviewed next.
Microcarrier systems. The development of microcarrier
cultures was a major breakthrough for anchorage-dependent
cells.80 Microcarriers are microscopic particles that are easily
maintained in suspension in liquid medium, providing a
pseudo-suspension culture for anchorage-dependent cells.4,81
They increase the surface area available for cell adhesion
and growth, allowing high cell density and productivity.82,83
Microcarrier characteristics, such as size, density, and sur-
face charge, are important for their applicability in industrial
technologies.10,11 They should be small to maximize growth
surface area, nontoxic, autoclavable, suitable for microscopic
monitoring of cell growth and have densities that allow them
to be easily kept in suspension, as well as good adhesion
properties and high batch-to-batch consistence.10,11 To pro-
vide such features, several materials have been tested for
microcarrier construction, including dextran, plastic, gelatin,
glass, collagen, silicone, and cellulose.10,11
Consequently, a variety of microcarriers are available (see
Table 2 for a selection of commercially available microcar-
riers and their main characteristics), and the choice should
be made according to the cell line and the purpose of the
culture.11 Generally, microcarriers can be classiﬁed into
micro- and macroporous. The original microporous carriers
(i.e., Cytodex 1, 2, and 3) have a small pore size that does
not allow cells to colonize the interior and, therefore, are
used only for external surface attachment.11 On the other
hand, macroporous carriers (i.e., Cytopore, Cytoline, and
Cultisphere) contain open channels, large enough for cells to
enter and continue growing, within each bead, providing an
increased surface area in comparison to microporous car-
riers.11 Consequently, the maximum cell density and produc-
tivity achieved is improved.10 Furthermore, macroporous
carriers may provide protection to shear-sensitive cells11,85
and are also suitable for the propagation of suspended cells
that are entrapped in the porous.10
To establish an efﬁcient process of microcarrier culture,
the full colonization of the available surface should be
assured,11,86 limiting the number of unoccupied beads at the
end of the culture, and achieving a higher cell yield. In proc-
esses where detachment of cells from microcarriers is
needed, proteolytic enzymes can be used. However, for the
production of secreted cell products, as mAbs, this is usually
unnecessary.11
Suspensions of microcarriers are usually maintained in
spinner ﬂasks for scale-up to large-scale bioreactors.11 Scale-
up of microcarrier cultures is easily accomplished by simply
adding new microcarriers into an existing culture, in larger
reactors.10,11 Cells then begin to colonize the new microcar-
riers, by bead-to-bead transfer11,87 or, more commonly, by
cell detachment from conﬂuent microcarrier surfaces, which
will occur in a low calcium medium or by a change of pH
for some cell lines, or by the use of a cocktail of trypsin and
ethilenediamine tetra acetic acid (EDTA) in other cases.10,11
STR is the most predominant bioreactor used for micro-
carrier culture.9,88,89 The density of microcarriers used in
this reactor differs with the mode of culture, with the higher
densities being used under fed-batch and perfusion modes
allowing increased cell concentrations (more than 107 cells/
mL) to be achieved.10,90 Perfusion is, indeed, the most used
operation mode for adherent culture with microcarriers in
STR.9,88 Retention of the microcarriers can be easily and
reliably achieved with spinﬁlters91,92 or other simpler means
such as stagnant zones.93 This is an advantage over suspen-
sion cultures in STR, where cell retention is harder to
achieve and problems such as ﬁlter fouling or incomplete
cell retention have been reported. Nevertheless, problems
related to agitation have still been encountered. To achieve a
good oxygen supply, certain levels of agitation are neces-
sary. However, cells adhered to the microcarriers are sensi-
tive to overagitation and can be detached above critical
stirrer rates.92,94 Furthermore, entrapment of microcarriers in
foam layers generated by direct sparging and the consequent
cell damage has also been observed.95
Fluidized bed bioreactors use porous microcarriers with a
speciﬁc gravity ([1.6) that allows them to stay suspended in
a high-velocity upward-ﬂuid ﬂow of culture medium.10 In
the initial design, this ﬂuidized bed was contained in a col-
umn-type bioreactor that was connected to an external recir-
culation loop, where a gas exchanger, sensors, heating
elements, and a circulation pump were located.10 The major
disadvantage of this reactor was the generation of an oxygen
gradient along the axis of the column. This limitation can be
overcome by the integration of a membrane oxygenation
module directly into the ﬂuidized bed96,97 or by the
Table 2. Properties of the Main Commercially Available Microcarriers (Adapted from Malda and Frondoza84)
Material Name Size (lm) Surface Area (cm2/g) Density (g/ml) Porosity Manufacturer
Dextran Cytodex 1 147–248 4,400 1.03 Micro Amersham Biosciences, Sweden
Cytodex 2 135–200 3,300 1.04 Micro Amersham Biosciences, Sweden
Hillex 150–210 350 1.10 Micro SoloHill, USA
Plastic Plastic coated 150–210 380 1.02–1.04 Micro SoloHill, USA
PlasticPlus coated 150–210 380 1.02–1.04 Micro SoloHill, USA
2D MicroHex 125 760 1.05 Micro Nunc, Denmark
Cytoline 2 400–2500 [1,000 1.03 Macro Amersham Biosciences, Sweden
Glass Glass-coated 150–210 380 1.02–1.04 Micro SoloHill, USA
Cellulose Cytopore 1 200–280 1,200 1.03 Macro Amersham Biosciences, Sweden
Gelatin Cultispher G 130–380 Not available 1.04 Macro Percell Biolitica, Sweden
Cultispher S 130–380 Not available 1.04 Macro Percell Biolitica, Sweden
Collagen Cytodex 3 141–211 2,700 1.04 Micro Amersham Biosciences, Sweden
Cellagen 100–400 Not available Not available Macro MP Biomedicals, USA
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integration of an in-line gasiﬁcation tube module.98 This last
ﬂuidized bed bioreactor (Figure 6) has an improved oxygen-
ation, resulting in its current use in biotech industry for
large-scale production of proteins for research and medical
applications.10 However, the available working volumes are
still very limited.10
Concerning disposable bioreactors, particularly wave, little
has been reported about its application for microcarrier cul-
tures,99 particularly for mAb production. Nevertheless, the
few studies performed, involving vaccine,48,54 adenovirus,51
and recombinant protein51 production, have shown successful
results on the use of wave for anchorage-dependent culture
using microcarriers.
Membrane and ﬁber bioreactors. Apart from the systems
using suspended microcarriers, other alternative bioreactors
and matrices for anchorage-dependent cell culture have been
tested.
Hollow ﬁber bioreactors (HFB, Figure 7) have been exten-
sively studied for mAb production,100,101 usually in perfusion
mode.100 These systems try to mimic the in vivo mammalian
cell environment. For that, cells immobilized at high density
are perfused via thousands of capillaries made from ultraﬁl-
tration or microﬁltration (semipermeable) membranes. The
culture medium contained in a reservoir circulates within the
capillaries by the action of a pump, bringing oxygen and
nutrients to the cells, and removing the waste products,
before returning to the reservoir for recirculation.102,103 The
oxygenation and pH control is achieved by a gas exchange
unit.102
The HFB systems generally achieve high cell densities
with high mAb volumetric productivities, consequence of the
use of semipermeable membranes that retain the secreted
product in the cell compartment, concentrating the product
before harvest.74,100 This results in products free from me-
dium-derived contaminants,102 but with more contamination
with dead cells and cell debris, which may put high demands
on the puriﬁcation process.74 The accumulation of dead cells
over time may also result in relatively short operation life.74
The capillary membrane separation between the cells and
the main medium ﬂow provides a low shear environment,
which is an advantage over the typical STR system.100,102
However, HFBs are difﬁcult to scale up,74 the large-scale
units are expensive, prone to membrane fouling, and have
many operation difﬁculties (mechanical failures and
improper feed controls). This may result in low cell viability,
process instability, and variable product quality.101,104
Fixed or packed bed reactors (FBR) are a widely used al-
ternative bioreactor technology for perfusion culture of im-
mobilized mammalian cells. These reactors are typically
composed of a packed bed that supports cells immobilized
on or within carriers, a gas exchanger, and a medium reser-
voir that is used to recirculate the oxygenated nutrient me-
dium through the bed.105,106 Therefore, cells are retained in
the ﬁxed-bed matrix and the spent medium containing the
product that returns to the reservoir can be harvested in
batch or continuous mode.74,102
FBR can be divided in two major designs (Figure 8): one
where the packed-bed compartment is external to the
medium reservoir, and the other where it is contained
Figure 6. Schematic diagram of the modular ﬂuidized bed bio-
reactor CytopilotTM (www6.gelifesciences.com).
Figure 7. Schematic diagram of a hollow ﬁber bioreactor.40
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within.77,107 Additionally, the medium ﬂow through the bed
may be parallel to its longitudinal axis or radial.74
Several matrices for cell immobilization have been tested.
The initial solid glass beads for growing cells as mono-
layers108 were abandoned because of low speciﬁc surface-to-
volume ratio that resulted in limited cell densities.74 This led
to the introduction of porous glass spheres that provided
higher speciﬁc surface, increasing cell densities.106 However,
the relatively low internal porosity of these spheres posed
some limitations to oxygen diffusion within the carriers.74
Therefore, the next generation of packing materials has
higher internal porosities, and includes glass ﬁbers,76 ceramic
matrix,109 nonwoven ﬁbers made of polydegradable poly-
mers such as polyglycolic acid (PGA) and polylactic acid
(PLA),110 and non-woven polyester ﬁbrous matrices.111 Sys-
tems with these carriers achieve high cell densities and pro-
ductivities,112,113 showing the great potential of FBR for
commercial use.114 This is mainly due to their characteristics
of high porosity and high speciﬁc surface area for cell adhe-
sion, good mass-transfer efﬁciency, relatively low pressure
drop and shear rates, ease of operation and scale up, and low
costs.74,107 The low shear rates observed in these bioreactors
favor the application of serum- or protein-free media.115 Fur-
thermore, the retention of cells in the bioreactor reduces
product contamination with cell-derived components, facili-
tating the downstream processing.102 Nevertheless, these sys-
tems still have some limitations that need to be surpassed,
like the severe clogging and channeling over long-term
use,60 the heterogeneity that can be observed (formation of
concentration and cell gradients),102 and still some oxygen
transfer limitations.116 Indeed, these last two limitations are
a major drawback to further scale-up of the FBR systems,
because of the maximum packed-bed depth of 30 cm they
impose. The bed diameter is also limited (2 m) because of
the difﬁculty of maintaining a uniform distribution of
nutrients over the bed. Consequently, the total volume of the
bioreactor becomes restricted, with the maximum FBRs vol-
ume reported being of 30 L.105
A derivation of the ﬁxed bed reactor consists of a dialysis
bioreactor with radial-ﬂow ﬁxed bed. In this reactor, the two
chambers (macroporous carriers-containing and medium-con-
taining) are separated by a cylindrical membrane. The aera-
tion is done in the outer chamber containing the medium
that radially ﬂows through the membrane and the cells in the
inner chamber, by induction of a centrifugal pump.117,118
Modes of operation
Bioreactors can operate in different modes of culture, with
the following being the commonly mentioned in literature:
batch, fed-batch, continuous culture without cell retention
(chemostat or cytostat), and continuous culture with cell
retention (perfusion).10,119 The choice of the best mode of
operation depends on the application for which it is
intended.
Batch Culture. Batch culture is a simple and reliable pro-
cess, and therefore, the method of choice for many industrial
applications.49,120 In this mode of operation, the bioreactor is
initially charged/inoculated with cells and medium,11 and the
cells are allowed to reach a determined density and product
concentration.49 At this point, the cell supernatant is col-
lected49 and the product of interest recovered. The scale-up
to larger volumes is simple and basically consists on diluting
the content of a bioreactor into 5–20 vol of fresh medium
kept prewarmed in a larger reactor.4
As no additions or withdrawals are performed during
batch culture, nutrient concentration will gradually decrease,
whereas waste product concentration increases, leading to a
gradually deteriorating environment for cell growth.11 There-
fore, the maximum cell density that is possible to reach (usu-
ally about 106 cells/mL) is dictated by nutrient limitation
(glucose, glutamine), waste product inhibition (ammonia,
lactate, CO2),
10,11,121 or the complete cover of the available
growth surface (for anchorage-dependent cells).11 This con-
tributes for the major limitation of batch culture—the
reduced cell yield that is possible to attain, which ultimately
results in reduced product concentrations. This limitation can
only be surpassed by nutrient supply and/or removal of
waste products,11 as it is attempted in other culture modes.
The time of harvest in batch culture is based on the
kinetics of product formation,122,123 that is, if the product
formation is growth or nongrowth associated. In the ﬁrst
case, the speciﬁc productivity increases with increasing
growth rate and ceases when the culture is entering station-
ary phase, whereas for the latter, product formation increases
with decreasing growth rate or is only observed during sta-
tionary phase.10 However, the quality of the product should
also be an aspect to consider when establishing the time of
harvest, because the continuously changing (degradative)
composition of the culture medium can affect the quality of
the earlier synthesized product.4
A derivation of batch mode of operation is the repeated
batch culture (batch-refeed), where a fraction of the cell sus-
pension is left in the bioreactor when the culture is harvested
and fresh medium is added for a new batch cycle.4,10 In this
operation, it is critical to assure a high viability of the
remaining cell suspension and to optimize the time to initiate
the new batch.10
Indeed, basic batch suspension processes have the tend-
ency to become less common, because waste accumulation
and nutrient ﬂuctuations can be reduced using nutrient feed-
ing strategies that allow higher cell densities and productiv-
ities.9 Although batch-refeed is the simplest of these
strategies, other more efﬁcient modes are also being used, as
fed-batch and perfusion.
Fed-Batch Culture. In fed-batch cultures, a controlled
nutrient feeding is performed during the course of the cul-
ture,11 in an attempt to increase the culture longevity (partic-
ularly important in the production of growth-associated
products),124,125 cell yield,11 and overall productivity.47
Figure 8. Schematic representation of a ﬁxed bed bioreactor
with (a) external and (b) internal recirculation of
medium (modiﬁed from104).
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Nutrient feeding strategies include partial medium changes
at regular intervals and the addition of speciﬁc nutrients at
critical stages of the culture.11,125 For this, the limiting
nutrients should be identiﬁed, so that the correct concentra-
tion of a speciﬁc nutrient is added at precise intervals.11,124
It is therefore implied that a better understanding of the
effects that culture conditions have on cell viability and anti-
body production is needed to establish the essential condi-
tions during a fed-batch operation, aiming for the
maximization of product formation.125
However, although fed-batch strategies can alleviate the
limiting effects of nutrient depletion, the accumulation of
waste products to growth-inhibitory concentrations is not
avoided/controlled.11 Nevertheless, the fed-batch process is
often used because of its scalability, ease of operation, and
high volumetric productivity.6,125
Continuous Culture. A continuous culture consists of an
open system with continuous feed of fresh medium and re-
moval of spent medium.11 This allows cell growth to pro-
ceed for longer periods than in a batch or fed-batch culture.
This continuous culture can be divided in two main types:
chemostat culture and perfusion culture.11
In chemostat culture, cells are removed continuously from
the bioreactor with the spent medium.126 Growth is con-
trolled by the ﬂow rate of fresh medium, expressed as dilu-
tion rate (medium ﬂow rate divided by the culture volume),
with common values of 0.2–1.0 vol/day (proportion of cell
culture volume replaced in 1 day) for mammalian cells.11
When the cell growth rate is equal to the dilution rate, a
steady state of equilibrium is reached, where concentrations
of cells, nutrients, and products are constant.11 These condi-
tions of steady state are always restored if a change occurs,
because of the self-regulation of the chemostat system. For
example, a temporary decrease in cell concentration will
cause a corresponding increase in the growth rate.11 In perfu-
sion culture, cells are retained in the bioreactor (e.g., by cen-
trifugation,127 internal and external spin ﬁlters,128,129 or
hollow ﬁber modules130,131), whereas the spent medium is
continuously replaced with a fresh supply.63,132 The continu-
ous supply of nutrients and removal of waste products, as
well as cell recycle, results in increased longevity, improved
cell density ([107 cells/mL), and, consequently, higher volu-
metric productivity.130,132 The residence time of the product
in the culture environment is also reduced, which results in
improved product quality.132,133 For large-scale production,
this system appears to be one of the most advantageous.
Process Monitoring
Mammalian cell cultures performed in bioreactors allow
the production of mAbs in large-scale quantities. However,
this production can be further maximized using different
strategies, such as nutrient optimization, feeding, cell engi-
neering, or manipulation of the cellular environment.134
Among these, the most common practice consists on the
optimization of bioreactor culture conditions, because it rep-
resents an economical and reliable way to ensure optimal
productivity.134 For this, the culture parameters more rele-
vant for cell growth and productivity need to be identiﬁed,
and their individual and interrelated effects better under-
stood. Furthermore, methods and technologies for monitoring
and control the physicochemical environment in which cells
are exposed are essential to achieve productivity improve-
ments in bioreactors.6
Parameters
In the optimization of productivity, a balance between cell
growth and mAb production6 needs to be achieved, because
the conditions that are optimal for a speciﬁc mAb may not be
the same for other. Nevertheless, process parameters, such as
temperature, pH, osmolarity, DO, CO2, and nutrient and
metabolites concentration, have been shown to affect cell per-
formance135 and are, therefore, generally seen as the most rel-
evant for optimization of production in mammalian cultures.
Temperature. Temperature is one of the most critical and
more studied variables to monitor for maintenance of healthy
cell cultures.136,137 Although the ideal growth temperature
for most mammalian cells is 37C (the body temperature), it
has been shown that this may not be the best temperature for
recombinant protein/mAb production. Indeed, some stud-
ies138,139 have demonstrated that a lower temperature
(around 30–35C) may have a positive outcome in terms of
mAb speciﬁc productivity, while maintaining or improving
product quality.135 However, the increase of the speciﬁc pro-
ductivity does not often results in improved volumetric pro-
ductivity, because of the negative effects that low
temperatures have in the cell growth rate.140 Therefore, the
most advantageous temperature strategy may be culturing
cells at 37C until a high cell density is reached and then
shifting to lower temperatures to achieve higher product
titers.141,142
pH. Along with temperature, pH is considered to be one
of the most critical parameters for mammalian cell culture,
because of the severe effects its variation can cause to
cells.10,143 Indeed, even small variations of pH (0.1) can
have impact on cell growth, productivity, cell metabolism,
and protein glycosylation.144,145 Furthermore, optimal pHs
for speciﬁc growth rate and speciﬁc protein production may
not be necessarily the same.145 In bioreactors, pH should
ideally be near 7.4 at the beginning of the culture and not
fall below 7.0 during culture,10,146 although values set
between 6.5 and 7.8 are usually acceptable.6 The highest val-
ues of pH are preferred for starting the culture because they
favor cell growth.6 However, they also increase the anaero-
bic cell metabolism that leads to the accumulation of metab-
olites (particularly lactate). Therefore, after reaching a
desired cell density, pH is usually shifted to a lower value
that, although halting cell growth,45,146,147 will improve mAb
production.6,147
Maintenance of pH stability in culture is affected by dif-
ferent factors, including buffer capacity and type,10,146 bio-
reactor headspace, and glucose concentration.146 Mammalian
cell culture medium is prepared with a buffer system to con-
trol pH variations, and it usually consists on the CO2 bicar-
bonate system.146 This system requires the addition of CO2
to the culture vessel headspace or the addition of bicarbonate
base.146 Nevertheless, other buffer systems can be used to
improve buffering and pH stability, such as the zwitterionic
buffer148 (i.e., Hepes), that can be used alone or in combina-
tion with bicarbonate, or specialist media such as Leibovitz’s
L-15.149
Because the normal buffer system needs a certain level of
CO2 (5%) to maintain a stable pH, it is important that the
culture vessel has a large headspace or an open system with
continuous ﬂow of air (required in large bioreactors). This
will assure that CO2 generated during cell growth adequately
diffuses from the medium, without build-up and consequent
decrease in pH.146
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In addition, glucose concentration in the medium also
affects pH. Glucose is metabolized by cells at a greater rate
than it is needed and results in the formation of toxic metab-
olites (pyruvic and lactic acids) that lower pH to nonphysio-
logical levels.146 To avoid the fast build-up of metabolites
and deterioration of the medium, glucose should be added in
small concentrations (no more than 2 g/L) to the medium
during culture. Other approach is to replace glucose by other
carbon sources, such as galactose or fructose, which signiﬁ-
cantly reduces formation of lactic acid, but also results in
slower cell growth. Nevertheless, in large bioreactors, a pH
control system is usually essential.146
Osmolarity. Osmolarity strongly inﬂuences mAb produc-
tion, cell growth, and death rates, as well as the duration of
exponential growth.124 Increases in osmolarity are observed
because of additions of base (to control pH) or of glucose or
medium concentrates to the culture.124,150 The resultant high
levels of osmolarity cause decreased growth rates and cell
concentrations. However, within a certain range (300–400
mOsm/kg), the osmolarity increase can be beneﬁcial. Indeed,
at this range, the negative consequences in cell growth can
be compensated with increases on the speciﬁc mAb produc-
tion rate, resulting in a higher ﬁnal antibody concentra-
tion.151 For this reason, hyperosmolarity is sometimes
described as one alternative to improve mAb production,
with the advantage of being more economical than
others.152,153
Dissolved Oxygen. Mammalian cells require oxygen for
the production of energy from organic carbon sources.10,143
Therefore, oxygen available for cell use (DO) is an impor-
tant parameter for mammalian cell culture. The amount of
DO in the medium is dependent on a diversity of factors,
such as cell growth rate, carbon source,10 and speciﬁc rate of
consumption by the cells,154 that leads to a state of dynamic
equilibrium of DO.10 Although DO may not negatively affect
cell growth and production levels within a large range (pO2
between 20 and 100% of air saturation),6,146 it can have neg-
ative consequences on product quality (glycosylation).6,155
Furthermore, scale-up represents a problem for guarantee-
ing correct levels of DO in the culture, because the methods
currently available for that purpose cannot assure high cell
oxygenation without causing some cell damage (see next
section).146
Carbon Dioxide. CO2 is known to have an essential role
in mammalian cell culture to maintain the culture pH at the
normal optimum range and to regulate many cellular activ-
ities.156 Therefore, the concentration of CO2 should be main-
tained at physiological levels (partial pressure of 50–70
mmHg at 37C157).158 However, during scale-up in large-
scale bioreactors, the CO2 partial pressure tends to build up
to levels higher than physiological, causing signiﬁcant prob-
lems in mammalian cell culture.159–161 In fact, it has been
shown that high dissolved CO2 concentrations can have det-
rimental effects on cell growth, nutrient utilization, product
formation (productivity), and product quality.158,162,163 These
detrimental effects must be carefully considered during opti-
mization of mammalian cell culture process, to achieve
higher productivities and better product quality.158,164
Nutrient and Metabolites Concentration. Nutrients pres-
ent in the medium are the support for cell growth, and their
exhaustion can jeopardize cell growth rates.146,164 Among
the nutrients needed for cell culture, glutamine and glucose
are considered as the most critical/limiting ones, which is
evident from the reduction of cell growth rate that occurs
even before these nutrients are totally consumed.146 Further-
more, as mentioned earlier, consumption of glucose by cells,
especially when present at high concentrations in the me-
dium, is done at a higher rate than necessary. This leads to
the rapid accumulation of toxic metabolites (lactate, ammo-
nia) that can inhibit cell growth and/or protein productiv-
ity,165 as well as affect product’s glycosylation.166 To avoid
this, some attempts have been made, which include reduction
of ammonia formation by controlling glutamine concentra-
tion,90 modiﬁcation of the energy metabolism by controlling
glucose concentration (e.g., by feeding less glucose to the
culture but more periodically, in concentrations according to
cell needs),165,167,168 or replacement of glucose by a slower
utilized substrate such as galactose.169
Apart from the control of the main nutrients, other com-
pounds may be added to the medium to reach an optimal
culture performance. These include growth factors and hor-
mones such as insulin, transferrin, ethanolamine, and
selenium.170
Glycosylation. Mammalian cell lines are the host of
choice for the production of therapeutic mAbs especially
because of their ability to perform correct post-translational
modiﬁcations, particularly glycosylation, which has a major
effect on the biological properties of the product (pharmaco-
kinetics, bioactivity, secretion, in vivo clearance, solubility,
receptor recognition, and antigenicity).171,172 Hence, it is
essential to ensure that a consistent glycosylation proﬁle is
maintained between batches in the process of production.6,173
However, culture conditions, such as temperature, pH,174
DO, CO2, osmolarity,
175 time of culture,176 as well as nutri-
ent and metabolite concentrations,174,175,177 have been shown
to affect glycosylation.6,178,179 Therefore, it is of extreme im-
portance to have a further understanding of the parameters
that control protein glycosylation in bioreactors, and to mon-
itor product quality during each step of the optimization, to
be able to ensure the quality and consistency needed for bio-
pharmaceutical production.6,171
On-line/off-line control
During bioreactor culture, it is important to assess the cul-
ture health. For this, several key parameters are routinely
measured, such as pH, DO, dissolved CO2, temperature,
nutrients and metabolites concentration, cell density and via-
bility, as well as product concentration and quality. Monitor-
ing these parameters allows the follow-up of culture growth
and metabolism, and in case of decline of cell health it helps
identifying the cause (starvation, bacterial contamination, or
bioreactor equipment failure). To be able to efﬁciently and
timely intervene in the culture to maintain cell health, this
monitoring should ideally be performed on-line, in real-time.
However, this is currently only possible for some parameters
(temperature, pH, DO, and dissolved CO2), whereas others
(cell density/viability, nutrient and metabolites concentration,
mAb concentration, and quality) are still analyzed using off-
line techniques.6 Nevertheless, efforts are being made to de-
velop methodologies that will allow the on-line monitoring
of such parameters.
Temperature. Temperature is a major player in culture
optimization, and as such, instrumentation and strategies
developed for its control should be highly accurate (0.5C
is considered adequate180).10 The most commonly used
instrumentation is the resistance temperature devices (RTDs)
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(usually made of platinum), which combine characteristics of
high accuracy, high reproducibility, and fast response time
with moderately high costs. With lower costs than RTDs are
the thermocouples that, however, give less accurate and sta-
ble temperature measurements.10
Control of temperature in mammalian cell cultures has
been using systems regulating the temperature or ﬂow rate
of water in an external water jacket or in internal heating or
cooling coils.10 Moreover, although in laboratory-scale bio-
reactors the control can be on-off, in larger bioreactors a
more precise control is needed. For this, proportional-integral
(PI) or proportional-integral-derivative (PID) control schemes
can be applied.181
pH. pH monitoring is currently performed on-line, using
an autoclavable pH probe (usually electrochemical probes143)
that feeds a signal that is transformed into an analogue or
digital display of the culture pH.146 This allows direct and
continuous measurements to be taken, providing information
on both growth and cellular metabolism, because they are
strongly dependent on medium pH.182,183
To control pH, maximum and minimum acceptable pH
values need to be set, so that pH is maintained within a
deﬁned range.146 If the culture pH drifts away from the
range established, the system activates pumps that add acid
or base to the culture to set it back into the desired val-
ues.10,146 Though, usually, only base additions are needed
(often KOH, NaOH, NaHCO2, or Na2CO3
10), since cell me-
tabolism results in pH decrease.10,146 Furthermore, the pH
monitoring system also involves control of the gas supply,
more particularly, CO2 additions to the medium. If pH is
above the set point, CO2 will be delivered to the culture, but
if it is below this value, only air, oxygen, or a mixture of
both will be added.146 Moreover, pH control is helped by the
buffering capacity of most mammalian cell culture media.10
Apart from glass electrodes, other methods have been
developed for pH quantiﬁcation, such as optical and ﬁber-op-
tical pH sensors.143,184,185 These sensors can be based on
conductive polymers, imaging ﬁbers, microparticles and
nanospheres, as well as micrometer, submicrometer, and dis-
tributed ﬁber-optic sensors. Other pH sensors include acidity
and alkalinity sensors, pH sensors with broad dynamic range
and linear response, and CO2 and NH3 sensors based on pH
indicators.
Dissolved Oxygen. The direct and continuous monitoring
of DO provides important information about growth and cel-
lular metabolism rates.183,186 For this, quantiﬁcation of DO
is usually performed amperometrically, using a Clark-type
electrode that consists of an electrode covered by a mem-
brane that is selectively permeable to oxygen.187 Addition-
ally, a spectrophotometric method based on a colorimetric
technique188 can be used, which has a sensitivity lower than
the amperometric method but still higher than needed for
cell culture.10 Another alternative is the use of oxygen sen-
sors based on ﬂuorescent quenching of suitable dyes,189,190
which show good stability and reversibility.10 Actually, opti-
cal sensors have been developed for the measurement of
oxygen levels in culture.143,185,191
To control the oxygen levels in culture, different methods
(or a combination) can be used. In smaller cultures, the
maintenance of a large headspace volume is extremely im-
portant and usually sufﬁcient to assure no oxygen limitation
to cells.146 In larger reactors, however, other methods need
to be used to guarantee adequate oxygen supply. These
include sparging, membrane diffusion, medium perfusion,
increasing of the partial pressure of oxygen, and increasing
of the atmospheric pressure.192
Sparging consists of bubbling gas through the cell culture
but, although very efﬁcient, it can cause damage to the cell
membrane because of the high surface energy of the bub-
bles.146 These negative effects can be minimized by using
larger air bubbles, a very low gassing rate or by adding Plur-
onic F-68 (a shear protectant) to the medium. For its turn,
the membrane diffusion method uses tubing of very gas-per-
meable silicone arranged in the bioreactor to achieve sufﬁ-
cient oxygen diffusion. However, because of the large
quantities of tubing required, the method is expensive and
inconvenient to use and also difﬁcult to scale-up.146
A more advantageous method is the medium perfusion, in
which the medium is continuously (or on demand) taken
from the culture and passed through an oxygenation chamber
before returning to the culture. As the medium is separated
from the cells, it can be conveniently sparged to ensure oxy-
gen saturation without damaging cells.146
Furthermore, when the bioreactor culture is already
advanced, DO concentration can be increased by raising the
headspace oxygen pressure (pO2) and/or the pressure of the
culture (to increase the oxygen solubility and diffusion
rate).146
Dissolved CO2. Although in mammalian cell culture DO
is the parameter most often used for on-line monitoring and
feed control,193 dissolved CO2 is another component of inter-
est that can be used as an indicative of the cellular metabo-
lism.10 CO2 measurements can be performed with ofﬂine
sensors, but these are limited by the low frequency of data
collection (not allowing continuous control) and the need for
sampling.157 Therefore, attempts to develop in situ CO2 sen-
sors have been made. Commonly, CO2 is quantiﬁed in the
gas phase using relatively inexpensive infra-red analyzers,
which require stable temperature and consistent levels of
moisture in the vapor environment.10 More recent techni-
ques, for CO2 quantiﬁcation in the medium, include sensors
that use a gas-permeable membrane to separate a bicarbonate
buffer from the analyte solution and a glass pH electrode,194
and optic ﬁber probes that use a pH sensitive dye and an op-
tical ﬁber (e.g., the commercialized YSI 8500 sensor).157,195
Other alternative methodologies to monitor CO2 include gas
chromatography and mass spectrometry, which has a rapid
response time and high sensitivity, being one of the most
promising techniques.10
Cell Density and Viability. The success of a mammalian
cell culture is typically evaluated by cell density and viabil-
ity, because the goal of a culture scale-up process is to maxi-
mize the total number of viable cells in the minimal amount
of time.196 The common practice for the assessment of cell
density and viability is to take daily samples from the bio-
reactor and to perform off-line measurements. The off-line
methodologies used can be direct or indirect197 and can
assess both density and viability or just one of these parame-
ters. For direct measurements, a hematocytometer is com-
monly used, allowing microscopic cell counting. In
conjugation with a dye exclusion test, it becomes possible to
simultaneously assess cell viability, based on the concept
that viable cells do not take up certain dyes (e.g., trypan
blue or erythrocin) in opposition to dead cells.146 Automated
cell counters are also available for direct assessment of cell
growth and viability (e.g., Microcyte,198 Nucleocounter,199
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and Guava PCA200),6 as well as colorimetric methods 3-
(4,5-Dimethylthiazol-2-41)-2,5-diphenyltetrazolium bromide
(MTT assay).5 On the other hand, indirect methodologies for
both density and viability analysis are usually based on met-
abolic activity (glucose or oxygen uptake; lactic, pyruvic
acid, or CO2 production) or the expression of a prod-
uct.146,201 Cell density can also be indirectly assessed by
total cell mass measurement through total protein or dry
weight determination.146
The indirect methods are not as accurate as the direct
techniques, because the correlations between the speciﬁc
metabolic rates measured and cell density/viability vary with
the growth phase of cells.146,202 Nevertheless, these methods
can be very useful in situations where cells cannot be
sampled, such as most anchorage-dependent cultures, or vis-
ually examined.146
Off-line measurements of these parameters are the common
procedure currently used. However, ideally, the assessment of
cell density and viability should be performed on-line, inside
the bioreactor, without the need for sampling. This would
allow a frequent or even continuous (real-time) monitoring,
providing early indications of catastrophic events as contami-
nation or cessation of growth,183 and helping to ensure that
medium additions to the culture occur at appropriate times.201
Strategies for such measurements have been developed and
include turbidity,203 oxygen uptake rate, dielectric spectros-
copy,204 near-infrared (NIR) spectroscopy,205 capacitance
detection204 ﬂow injection ﬂow cytometry,206,207 optical mi-
croscopic imaging,208 CEDEX cell counter,201 and optical
sensors.143 However, most of these methods have low sensi-
tivity or are affected by medium debris and are usually unable
to measure cell concentrations below 5  105 cells/mL.201
Nutrient and Metabolites Concentration. Culture health
is strongly dependent on nutrient and metabolite concentra-
tions in the medium. Therefore, efforts have been made to
develop methodologies for monitoring these parameters.
Because of its importance, glucose and glutamine, as well as
their metabolic products (ammonia, lactate, and glutamate)
are the main concern in such developments. However, recent
evidence suggests that monitoring of a greater number of
components in bioreactors may be needed to sustain a health
culture.209 Indeed, ideally, all or nearly all of the high-level
components in a cultivation should be tracked.
Although, currently, nutrient and metabolite monitoring
still focus mostly on the main components, with the common
practice consisting of taking period samples from the bio-
reactor and performing off-line analysis, this analysis usually
involves high-performance liquid chromatography
(HPLC)6,167,168 or the recent and faster ultra-performance
liquid chromatography (UPLC)210–212 (amino acids), com-
mercially available analyzers such as the YSI analyzer (glu-
cose, lactate, ammonia)6,167,168,213 and enzyme-based or
spectrophotometric assay kits (ammonia, glutamine).10,167,168
Developments on on-line control include methods of chro-
matography, enzymatic conversions, ﬂow injection, and opti-
cal sensing.214 On-line chromatography analysis was the ﬁrst
to be applied, but it requires substantial time for measure-
ments and the periodic removal of samples, implying a risk
of bioreactor contamination and loss of some amount of
product.10 In this sense, enzymatic sensors can be very use-
ful, as they provide rapid measurements from within the bio-
reactor.10 However, these sensors have problems related to
the need for frequent recalibrations and for the separation of
the enzyme from the bioreactor environment, and therefore,
measurements using these enzymatic biosensors are usually
performed off-line.10
Another technology developed for on-line monitoring is
the ﬂow injection analysis (FIA), which uses different detec-
tion methods, namely amperometry, potentiometry, ﬂuores-
cence, chemiluminescence, UV–vis absorbance, or
turbidometry.215 FIA has a low risk of contamination, is
easy to recalibrate, requires small samples, and provides a
rapid analysis.10 It has been used for measurements of glu-
cose,216,217 glutamine,216 glutamate,188 ammonia,218 and lac-
tate217 concentrations. Though, each FIA sensor can monitor
only one analyte and often does not possess enough sensitiv-
ity and selectivity.219
The need for sampling from the reactor before analysis
can be eliminated by the use of spectroscopic methods. They
allow real-time monitoring of multiple analytes without sam-
ple preparation and in a noninvasive and nondestructive
way.10 These optical sensors can use visible, UV, or NIR
light and have been applied in the measurement of glu-
cose,220–222 glutamine,220–222 ammonia,220,222 lactate,220,222
glutamate,222 sucrose,223 fructose,223 maltose,224 and aspara-
gines221 concentrations.
MAb Concentration. Conventionally, mAb production is
quantiﬁed using methods as the standard enzyme-linked im-
munosorbent assay,225 Western blot, protein A HPLC, and
bioassays.226 However, these methods are time-consuming,
variable, and require substantial amounts of cell culture sam-
ples.226,227 Therefore, methods allowing real-time monitoring
of mAb concentration would be extremely useful to acceler-
ate cell line screening and optimization of culture
parameters.227
For this purpose, the use of ﬂuorescence intensity has been
tested, and it has been observed that it allows the screening of
a higher number of clones than the conventional assays. This
signiﬁcantly reduces the effort and time spent for screening
and improves the chances of identifying high producers.228
More recently, a mass spectrometer connected to a bioreactor
has been used to quantify multiple proteins in the culture
media,229 as well as a surface plasmon resonance-based bio-
sensor that allows on-line follow-up of the relative concentra-
tion of the protein of interest.226 This last method has showed
potential to on-line analysis of protein bioactivity.226
Furthermore, innovative approaches have been emerging
from the nanotechnology ﬁeld, which will enhance sensitiv-
ity to the level of single molecule detection. These include
metallic nanostructures (with unique optical properties) for
the detection of biomolecule interactions,230,231 combination
of metallic nanoparticles and nanoﬁlms with ﬂuorescent
probes,232,233 and combination of metal-enhanced ﬂuores-
cence and phase modulation ﬂuorometry.227
These advances will contribute for the development of
compact benchtop or handheld instruments for mAb quantiﬁ-
cation, similar to those routinely used for glucose
monitoring.227
Post-Translational Modiﬁcations. Post-translational proc-
essing is required to obtain a fully biologically active mAb.
Among the post-translational modiﬁcations, glycosylation is
one of the most important,175 playing critical roles in protein
folding, activity, immunogenicity, and protease sensitivity in
vivo.234 Several techniques are available to analyze glycosy-
lation of the product obtained from mammalian cell cul-
ture.235 This analysis is important to ensure quality and
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stability of the product, as well as batch consistency, and
can be based on different physical or chemical characteristics
of the glycoprotein.10 Broadly, four methods can be used: (i)
separating the glycoprotein by glycoforms, (ii) determining
the glycoprotein monosaccharide content, (iii) cleaving oligo-
saccharides from the glycoprotein, and (iv) degrading the gly-
coprotein via peptidases.236 To meet FDA requirements of
glycoprotein characterization, at least two of these analytical
methods need to be performed.10 For each of these methods,
different techniques can be used, with the more common
being electrophoresis, liquid chromatography (LC), mass spec-
trometry (MS), nuclear magnetic resonance (NMR), and exo-
glycosidase digestion.10,237,238 The choice of the appropriate
technique is based on several factors, namely the amount of
sample required, cost per sample, desired resolution, and
availability of equipment and technical expertise.10
For the ﬁrst method, whole or intact proteins are directly
analyzed based on size, charge, afﬁnity, and oligosaccharide
content, using sodium dodecyl sulfate polyaceylamide gel
electrophoresis (SDS-PAGE), isoelectric focusing polyacryl-
amide gel electrophoresis (IEF-PAGE), ion exchange chro-
matography (IEC), 2D-PAGE, Western blots, capillary
electrophoresis (CE), matrix-assisted laser desorption ioniza-
tion mass spectrometry (MALDI-MS), and exoglycosidase
digestion.10 This method is relatively easy, fast, and inexpen-
sive, but only allows a low level of resolution for the glyco-
sylation analysis.10,238 For these reasons, this analysis is
commonly used only to assess batch consistency of protein
glycosylation.239
The second method involves the analysis of monosaccha-
rides that are obtained directly from an intact glycoprotein or
glycopeptides pool.10 Such analysis can be performed by differ-
ent analytical techniques as ﬂuorophore-assisted carbohydrate
electrophoresis (FACE), HPLC,240 MALDI-MS, and NMR,
which give more detailed information about identity, composi-
tion, anomericity, and linkages of the monosaccharides.10
In the third method, oligosaccharides are obtained from
glycoproteins and glycopeptides (chemically or enzymati-
cally)239,241 and analyzed, with varied degrees of accuracy,
by FACE, CE, HPLC, fast-atom bombardment mass spec-
trometry (FAB-MS), electrospray mass spectrometry (ES-
MS), MALDI-MS, liquid chromatography mass spectrometry
(LC-MS),238 NMR, or exoglycosidase digestion.10 Informa-
tion about mass, composition, linkages, and sequence can be
obtained,10 with LC-based methods being the most accurate.
The last method also allows the analysis of glycopeptides
that are obtained from the proteolytic digestion of the glyco-
protein. For this, the techniques used are IEF-PAGE, CE,
HPLC, FAB-MS, ES-MS, MALDI-MS, LC-MS, and exogly-
cosidase digestion.10
Besides glycosylation, other post-translational modiﬁca-
tions are important to maintain the structure and function of
a mAb molecule, such as deamidation, isomerization, oxida-
tion, proteolysis, and aggregation.174,242 The methods typi-
cally used to analyze these modiﬁcations include cation-
exchange chromatography (CEX),243 isoelectric focusing
(IEF),243 hydrophobic interaction chromatography (HIC),244
CE,245 MS,243 and reverse-phase HPLC-MS (RPLC-MS).246
Scale-Up
The aim of process scale-up is to obtain larger quantities
of the product, maintaining high levels of productivity and
product quality.247 For this, both physical (conﬁguration of
the bioreactor) and chemical requirements of cells have to
be satisﬁed, so that cells are kept in the proper physiological
environment. However, satisfying these requirements during
scale-up to industrial level is a challenging process, since the
many different factors involved interconnect and sometimes
compete between themselves.60,247,248
Parameters such as temperature, DO, and pH are all vol-
ume independent and, therefore, are set for larger bioreactors
at the same levels as for smaller bioreactors.248 On the other
hand, the total air ﬂow rate as well as CO2 and oxygen ﬂow
rates have to be changed according to the culture working
volume, to maintain a normalized volumetric ﬂow rate. This
is simply obtained by dividing the total air ﬂow rate by the
volume.248 However, because of problems related with low
mixing rates, accumulation of CO2 becomes a recurrent issue
in scale-up,160,161 because it has been shown to cause inhibi-
tory effects on cell growth and antibody production152,160,162
and quality.159
Indeed, the agitation rate is one of the most critical249 and
difﬁcult parameters to scale-up, because it needs to provide
sufﬁcient mixing (for good mass transfer and homogeneity)
in the larger bioreactors and, simultaneously, not cause too
much stress and damage to the cells.45,248,249 A good balance
is hard to attain, and usually pH and nutrient gradients are
present in large-scale bioreactors because of poor mix-
ing,250,251 which result in reduced cell growth and antibody
production.252
Moreover, changes on the agitation speed may impact
other parameters that should be maintained during scale-up,
such as the critical253 oxygen transfer coefﬁcient.248 There-
fore, this will imply the adjustment of other conditions that
would otherwise be simple to scale-up.
During scale-up, nutrient limitation is another factor to
consider, with feed additions needing some adjustments.
Although the schedule of feed additions is maintained across
scales, the feed volume and rate need to be changed accord-
ing to the volume.248 As the feed stock is usually more con-
centrated for large-scale production, because of ease of
preparation, handling, and storage, this concentration factor
should also be considered in the scale-up.248 Furthermore, in
large-scale bioreactors the delivery of multipulse feeds is
usually combined as a single addition to save time and ease
of operation. This may imply a change on the method of
delivery of the feed media.248
Finally, inoculation and sampling is modiﬁed in large-
scale bioreactors. Cell concentration should be kept constant
across scales. For this, inoculation at different scales should
use an inoculum of the same in vitro age (to maintain a sim-
ilar starting biological status of cells) and a similar inoculum
percentage (v/v) (to yield a comparable volume increase
from inoculation). For its turn, the frequency and size of cul-
ture sampling must be deﬁned for each scale. Particularly,
the volume losses during sampling should be carefully
accounted for in developing the scale-up strategy.248
Conclusions
With the recent advances in medicine, mAbs have
assumed an increased importance in the biopharmaceutical
industry, especially because of their characteristics of speci-
ﬁcity and selectivity.9 Indeed, currently, they are the fastest
growing biopharmaceutical product, with applications in
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diagnosis and therapy.164 Furthermore, the need for high
doses of mAbs has led to the rapid development of processes
for their large-scale production in mammalian cells, to cope
up with the market demands.8 Consequently, several produc-
tion systems have emerged, with speciﬁc characteristics, that
can be used for different applications, such as adherent or
suspension cell culture. However, the systems developed still
have major limitations, especially in oxygenation, monitor-
ing, and control of culture conditions, making it currently
difﬁcult to reach the full potential of mammalian cells for
mAb production.
To surpass these limitations, a greater knowledge on cells
and on the diversity of factors that affect their growth and
productivity, as well as the factors interactions has to be
obtained. Furthermore, more comparative studies about the
production technologies already available are still needed.
The combination of an increased know-how about technolo-
gies and cell behavior will allow the implementation of
more sustained and structured processes of optimization,
replacing the current practices based on empirical knowledge
and trial-and-error experimentation. This may result in the
development of new platforms of cell-culture processes for
mAb production that will reduce costs, simplify the proce-
dures, and ultimately speed-up the delivery of the new prod-
ucts to the market.
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